An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2617-2626

  Gervasoni Jr , James E ^b   Hindenburg, Alexander A ^c   Vezeridis, Michael P ^a   Schulze, Scott ^b   Wanebo, Harold J ^a   Mehta, Shashikant ^a,d  

^a BOSTON UNIVERSITY   (United States)

^b SETON HALL UNIVERSITY   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

Apoptosis; Daunorubicin; Necrosis; Paclitaxel; Pancreatic carcinoma cells

Indexed keywords

CISPLATIN; DAUNORUBICIN; DOXORUBICIN; ENZYME PRECURSOR; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PROCASPASE 3; PROCASPASE 8; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CONCENTRATION RESPONSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASES; CELL LINE, TUMOR; CISPLATIN; DAUNORUBICIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; NECROSIS; PACLITAXEL; PANCREATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 6444242767     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolen S and Wingo PA: Cancer statistics. CA Cancer J Clin 47: 5-27, 1997.
2. Lillemore KD: Current management of pancreatic carcinoma. Ann Surg 227: 133-148, 1995.
3. Grindey GB, Hertel LW and Plunkett W: Cytotoxicity and anti-tumor activity of 2′ 2′-difluoro-2′-deoxycytidine (gemcitabine). Cancer Invest 8: 313-318, 1990.
4. Tomikawa M, Kubota T, Takahashi S et al: Chemosensitivity of human pancreatic cancer cell lines serially transplanted in nude mouse. Anticancer Res 18: 1059-62, 1998.
5. Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. In: (editors) DeVita VT Jr, Hellman S, Rosenburg SA. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia: J.B. Lippincott Co., pp. 1126-1161, 2001.
6. Sawabe Y, Yamagishi H and Yamaguchi N: In vitro chemosensitivity of human pancreatic cancer cell lines. Int J Pancreatol 20(3): 185-90, 1996.
7. Hannum YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89(6): 1845-53, 1997.
8. Kumar S and Lavin MF: The ICE family of cysteine proteases as effectors of cell death. Cell Death Diff 3: 255, 1996.
9. Tartaglia L, Rothe M, Hu YF and Goeddel DV: Tumor necrosis factors cytotoxicity activity is signaled by the p55 TNF receptor. Cell 73: 213, 1993.
10. Suda T, Takahashi T, Goldstein P and Nagata S: Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75: 1169, 1993.
11. Rehemtulla A, Hamilton CA, Chinnaiyan AM and Dixt V: Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem 272: 257-83, 1997.
12. Smyth MJ and Trapani JA: Granzymes: Exogenous proteinases that induce target cell apoptosis. Immunol Today 16: 202, 1995.
13. Finkel E: Does cancer therapy trigger cell suicide. Science 286: 2256-58, 1999.
14. Ruefli AA, Smyth MJ and Johnstone RW: HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 95(7): 2378-2385, 2000.
15. Bruns CJ, Harbison MT, Kuniyasu H, Eue I and Fidler IJ: In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1(1): 50-62, 1999.
16. Boersma L et al: Quantification of apoptotic cells with fluorescein isothiocyanate-labeled Annexin V in Chinese hamster ovary cell cultures treated with cisplatin. Cytometry 24: 123-130, 1996.
17. Oridate N, Suzuki S, Higuchi M et al: Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 89: 1191-98, 1997.
18. Sikic BI and Dumontet C: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17(3): 1061-1070, 1999.
19. Johnson SA and Richardson DS: Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Reviews 11: 201-23, 1997.
20. Fang G, Chang BS, Kim CN et al: Loop domain is necessary for Taxol-induced mobility shift and phosphorylation of Bcl-2 as well as inhibiting Taxol-induced cytosolic accumulation of cytochrome c (cyt c) and apoptosis. Cancer Res 55: 3202-08, 1998.
21. Mansat V, Bettaieb A, Levade T et al: Serine protease, inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. FASEB J 11; 695-702, 1997.
22. Mansat-da Mas V, Bezombes C, Quillet-Mary A et al: Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol 56(5): 867-74, 1999.
23. Hahn SM, Liebmann JE, Cook J et al: Taxol in combination with doxorubicin or etoposide. Cancer 72: 2705-11, 1993.
24. Paridaens R, Biganzoli L, Bruning P et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000.
25. Gianni L, Munzone E and Capri G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
26. Syrigos KN, Michalaki B, Alevyzaki A et al: A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 22: 3583-3588, 2002.